Candel Therapeutics Inc. (CADL)
| Bid | 5.67 |
| Market Cap | 284.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -39.58M |
| EPS (ttm) | -1.33 |
| PE Ratio (ttm) | -4.27 |
| Forward PE | -2.72 |
| Analyst | Buy |
| Ask | 5.73 |
| Volume | 1,222,643 |
| Avg. Volume (20D) | 1,102,263 |
| Open | 5.34 |
| Previous Close | 5.35 |
| Day's Range | 5.21 - 5.70 |
| 52-Week Range | 3.79 - 14.60 |
| Beta | -0.91 |
About CADL
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for CADL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
6 days ago · proactiveinvestors.com
Candel Therapeutics posts Q1 profit, eyes 2026 BLA submission for prostate cancer drugCandel Therapeutics Inc (NASDAQ:CADL) reported a quarterly profit and said it remains on track to submit a biologics license application (BLA) in late 2026 for its lead cancer therapy, CAN-2409, aimed...
1 month ago · proactiveinvestors.com
Candel Therapeutics reveals new data showing better outcomes for glioma patients using CAN-2409Candel Therapeutics Inc (NASDAQ:CADL) shared promising results from a Phase 1b clinical trial testing its experimental cancer therapy, CAN-2409, in patients with newly diagnosed high-grade glioma—a pa...
1 month ago · proactiveinvestors.com
Candel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMICandel Therapeutics Inc (NASDAQ:CADL) earlier this week shared updated clinical data from a Phase 2a study evaluating its immunotherapy candidate CAN-2409 in patients with advanced non-small cell lung...
1 month ago · proactiveinvestors.com
Candel Therapeutics reports positive survival data for CAN-2409 in advanced lung cancer trialCandel Therapeutics Inc (NASDAQ:CADL) said on Wednesday that its experimental immunotherapy, CAN-2409, demonstrated prolonged median overall survival in a Phase 2a clinical trial for patients with adv...
2 months ago · proactiveinvestors.com
Candel Therapeutics partners with IDEA Pharma on commercialization of lead asset CAN-2409Candel Therapeutics Inc (NASDAQ:CADL) announced that it has partnered with IDEA Pharma to advance the commercialization of its lead immunotherapy candidate CAN-2409. The collaboration follows positive...
2 months ago · proactiveinvestors.com
Candel Therapeutics appoints cancer immunology expert to research advisory boardCandel Therapeutics Inc (NASDAQ:CADL) said on Tuesday it has appointed Dr Elizabeth Jaffee to its research advisory board. Jaffee, an internationally recognized expert in cancer immunology and pancrea...